Today’s pharmaphorum podcast addresses the subject of speed – the velocity at which biopharma is bringing new therapies and medicines to market faster.
Next-generation technology is enabling drug discovery at an entirely new scale, accelerating the process, transforming therapies and advancing precision medicine, and resulting in better pa
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.